SIRT2 and Parkinson disease: The scaffolds of 3-(N-arylsulfamoyl) benzamide and 5-((3-amidobenzyl) oxy) nicotinamides may provide other options to explore more SIRT2 inhibitors as a potential therapy for Parkinson’s disease [129,130].